Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BGLC BioNexus Gene Lab	$5.63 -1.6%	$5.01	$2.01 ▼ $15.60	$10.13M	5.34	1.18 million shs	31,788 shs
BRTX Biorestorative Therapies	$1.53 +1.3%	$1.57	$1.21 ▼ $2.55	$12.21M	76.7	206,247 shs	23,781 shs
CCM Concord Medical Services	$5.50 +1.3%	$5.53	$3.80 ▼ $10.77	$23.88M	-0.94	21,120 shs	1,979 shs
MRAI Marpai	$1.37 -0.7%	$1.35	$0.40 ▼ $1.68	$23.66M	4.66	16,693 shs	32,855 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BGLC BioNexus Gene Lab	+7.32%	+6.72%	+12.16%	+94.56%	+31.90%
BRTX Biorestorative Therapies	+1.74%	+0.65%	-9.05%	-9.05%	-10.63%
CCM Concord Medical Services	+0.46%	+4.44%	-4.51%	-24.69%	-25.82%
MRAI Marpai	-1.43%	-1.43%	-4.17%	-0.72%	+206.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BGLC BioNexus Gene Lab	0.03 of 5 stars	0.0	2.0	0.0	0.0	0.5	0.0	0.0
BRTX Biorestorative Therapies	2.539 of 5 stars	0.0	5.0	0.0	0.0	2.9	3.3	0.6
CCM Concord Medical Services	0.5186 of 5 stars	0.0	3.0	0.0	0.0	0.6	1.7	0.6
MRAI Marpai	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
BGLC BioNexus Gene Lab	N/A	N/A	N/A
BRTX Biorestorative Therapies	N/A	N/A	N/A
CCM Concord Medical Services	N/A	N/A	N/A
MRAI Marpai	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BGLC BioNexus Gene Lab	$9.51M	1.07	N/A	N/A	$4.19 per share	1.34
BRTX Biorestorative Therapies	$605.20K	20.17	N/A	N/A	$0.61 per share	2.51
CCM Concord Medical Services	$383.96M	0.06	N/A	N/A	$51.05 per share	0.11
MRAI Marpai	$34.87M	0.68	N/A	N/A	($1.72) per share	-0.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BGLC BioNexus Gene Lab	-$1.60M	N/A	0.00	∞	N/A	-30.70%	-35.54%	-29.08%	N/A
BRTX Biorestorative Therapies	-$8.98M	-$1.27	N/A	N/A	N/A	-1,772.40%	-137.00%	-88.31%	N/A
CCM Concord Medical Services	-$42.23M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MRAI Marpai	-$28.75M	-$0.87	N/A	∞	N/A	-85.70%	N/A	-100.23%	N/A

Latest BGLC, MRAI, CCM, and BRTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/18/2025	Q2 2025	BGLC BioNexus Gene Lab	N/A	-$0.34	N/A	-$0.34	N/A	$2.26 million
8/12/2025	Q2 2025	BRTX Biorestorative Therapies	-$0.41	-$0.30	+$0.11	-$0.30	$0.34 million	$0.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BGLC BioNexus Gene Lab	N/A	N/A	N/A	N/A	N/A
BRTX Biorestorative Therapies	N/A	N/A	N/A	N/A	N/A
CCM Concord Medical Services	N/A	N/A	N/A	N/A	N/A
MRAI Marpai	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BGLC BioNexus Gene Lab	N/A	3.63	3.44
BRTX Biorestorative Therapies	N/A	2.07	2.07
CCM Concord Medical Services	1.67	0.46	0.45
MRAI Marpai	N/A	0.82	0.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BGLC BioNexus Gene Lab	18.85%
BRTX Biorestorative Therapies	69.38%
CCM Concord Medical Services	N/A
MRAI Marpai	49.75%

Insider Ownership

Company	Insider Ownership
BGLC BioNexus Gene Lab	0.70%
BRTX Biorestorative Therapies	30.80%
CCM Concord Medical Services	46.50%
MRAI Marpai	46.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BGLC BioNexus Gene Lab	30	1.80 million	1.78 million	Not Optionable
BRTX Biorestorative Therapies	7	7.98 million	5.52 million	Not Optionable
CCM Concord Medical Services	970	4.34 million	2.32 million	Not Optionable
MRAI Marpai	150	17.27 million	5.61 million	No Data

BGLC, MRAI, CCM, and BRTX Headlines

Recent News About These Companies

Marpai, Inc. Reports Significant Q2 2025 Turnaround

August 14, 2025 | tipranks.com

Marpai, Inc. (MRAI) Q2 2025 Earnings Call Transcript

August 14, 2025 | seekingalpha.com

MARPAI REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

August 13, 2025 | prnewswire.com

MARPAI TO HOST WEBCAST ON AUGUST 14, 2025 TO DISCUSS SECOND QUARTER 2025 FINANCIAL RESULTS

August 7, 2025 | prnewswire.com

MARPAIRX REVOLUTIONIZES PHARMACY BENEFITS WITH UNPRECEDENTED TRANSPARENCY AND SAVINGS

July 24, 2025 | prnewswire.com

Earnings call transcript: Marpai posts improved Q1 2025 results amid cost cuts

May 17, 2025 | uk.investing.com

Marpai, Inc. Reports Q1 2025 Financial Results

May 15, 2025 | tipranks.com

Marpai targets cash flow positivity in 2025 with cost reductions and leadership changes

May 15, 2025 | msn.com

Marpai, Inc. (MRAI) Q1 2025 Earnings Call Transcript

May 15, 2025 | seekingalpha.com

Marpai appoints new COO to accelerate growth

May 15, 2025 | uk.investing.com

MARPAI REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

May 14, 2025 | prnewswire.com

MARPAI HIRES DALLAS SCRIP AS CHIEF OPERATING OFFICER

May 13, 2025 | prnewswire.com

Market Access RICI Agriculture UCITS (MRAI)

May 8, 2025 | investing.com

MARPAI TO HOST WEBCAST ON MAY 15, 2025 TO DISCUSS FIRST QUARTER 2025 FINANCIAL RESULTS

May 7, 2025 | prnewswire.com

Marpai, Inc. to Present at the Planet MicroCap Showcase Las Vegas

April 15, 2025 | prnewswire.com

Marpai targets profitability in 2025 with new initiatives and strategic partnerships

March 27, 2025 | msn.com

Marpai, Inc. (MRAI) Q4 2024 Earnings Call Transcript

March 27, 2025 | seekingalpha.com

MARPAI REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

March 26, 2025 | prnewswire.com

MARPAI TO HOST WEBCAST ON MARCH 27, 2025 TO DISCUSS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

March 20, 2025 | prnewswire.com

MARPAI ACCELERATES HEALTHCARE TRANSFORMATION WITH EMPARA COLLABORATION, LAUNCHING UNIFIED HEALTH ENGAGEMENT PLATFORM

March 18, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGLC, MRAI, CCM, and BRTX Company Descriptions

BioNexus Gene Lab NASDAQ:BGLC

$5.63 -0.09 (-1.57%)

Closing price 04:00 PM Eastern

Extended Trading

$5.52 -0.11 (-1.97%)

As of 06:44 PM Eastern

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

Biorestorative Therapies NASDAQ:BRTX

$1.53 +0.02 (+1.34%)

Closing price 03:50 PM Eastern

Extended Trading

$1.52 -0.01 (-0.33%)

As of 04:04 PM Eastern

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

Concord Medical Services NYSE:CCM

$5.50 +0.07 (+1.29%)

As of 03:10 PM Eastern

Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.

Marpai NASDAQ:MRAI

$1.37 -0.01 (-0.72%)

As of 03:57 PM Eastern

Marpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, bill review and cost containment services. Marpai, Inc. was incorporated in 2021 and is based in Tampa, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time